Webb NJA, et al. - Via conducting this double blind, placebo controlled, randomised controlled trial across 125 UK National Health Service district general hospitals and tertiary paediatric nephrology centres, researchers determined whether extending initial prednisolone treatment in children with idiopathic steroid-sensitive nephrotic syndrome from 8 to 16 weeks improves the pattern of relapse of the disease. Study participants included 237 children (aged 1-14 years) with a first episode of steroid sensitive nephrotic syndrome. According to findings, clinical outcomes in UK children with steroid-sensitive nephrotic syndrome did not improve when the initial course of prednisolone treatment was extended from 8 to 16 weeks. Evidence of a short-term economic health benefit was found, however, through reduced use of resources and increased quality of life. Concerns about adverse events were not supported from exposing children to extended prednisolone treatment.